Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
205 Clinical Trials near Albert Lea, MN
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerOral Vaccine for COVID-19
Mankato, Minnesota
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune, Immunodeficiency, Cancer, Others
Must Not Be Taking:Antibiotics, Antacids, NSAIDs, Others
10400 Participants Needed
Obeldesivir for RSV Infection
Mankato, Minnesota
The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it is in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers want to see if obeldesivir can help participants' symptoms get better faster.
The primary objectives of this study are to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Hospitalization, Influenza, SARS-CoV-2, Others
Must Not Be Taking:Antimicrobials, Antivirals, Monoclonal Antibodies
150 Participants Needed
SAR443765 for Asthma
Mankato, Minnesota
This trial tests an injectable medication called SC lunsekimig in adults aged 18 to 80 with moderate-to-severe asthma. The medication aims to reduce lung inflammation and open airways, helping patients breathe more easily.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:COPD, Smoking, Tuberculosis, Others
Must Be Taking:ICS Therapy
685 Participants Needed
AFX3772 Vaccine for Pneumococcal Infections
Mankato, Minnesota
This trial tests a new vaccine called AFX3772 in healthy infants to prevent pneumococcal disease. The vaccine aims to help their immune systems recognize and fight off the bacteria that cause this disease.
No Placebo Group
Trial Details
Trial Status:Completed
Trial Phase:Phase 2
Age:42 - 90
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Allergies, Bleeding Disorders, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids, Immunoglobulins, Others
388 Participants Needed
Taletrectinib for Non-Small Cell Lung Cancer
Rochester, Minnesota
This trial is testing taletrectinib, a new drug, in patients with advanced lung cancer that have a specific genetic change. Taletrectinib is taken orally and aims to stop cancer growth by blocking this genetic change.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Lung Disease, Infections, Others
Must Not Be Taking:CYP3A4/5 Inhibitors, QT Prolonging
217 Participants Needed
PDS0101 + Pembrolizumab for Head and Neck Cancer
Rochester, Minnesota
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Infection, Autoimmune Disease, Others
Must Not Be Taking:Immunosuppressants, Live Vaccines
95 Participants Needed
Ascorbic Acid + Chemotherapy for Lymphoma
Mankato, Minnesota
This trial tests if adding high doses of vitamin C to standard chemotherapy can better treat certain cancers that have returned or are resistant to treatment. The goal is to see if vitamin C makes the chemotherapy more effective at killing cancer cells. The study focuses on patients with specific types of lymphoma, CCUS, and CMML. High-dose intravenous vitamin C (IVC) has been explored for its potential to enhance the effectiveness of cancer chemotherapy, with some clinical evidence suggesting benefits, though rigorous data are lacking.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Infection, Heart Failure, Others
Must Be Taking:Platinum-based Regimens
80 Participants Needed
Probiotic R-3750 for Ulcerative Colitis
Rochester, Minnesota
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis.
Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Severe UC, Active Infection, Autoimmune, Others
Must Be Taking:Aminosalicylates
36 Participants Needed
Serabelisib + Diet/Nab-paclitaxel for Solid Cancers
Rochester, Minnesota
This trial is testing a new cancer drug called serabelisib with a special diet that lowers insulin levels, and sometimes with another drug called nab-paclitaxel. nab-Paclitaxel is used for treating triple-negative breast cancer. It targets cancer patients who suffer from severe side effects of current treatments. The goal is to block cancer growth pathways and lower insulin to reduce side effects and improve treatment effectiveness.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Brain Tumor, Diabetes, Cardiac Disease, Others
Must Not Be Taking:PI3K Inhibitors, Insulin, Antacids, Others
68 Participants Needed
Serial Amnioinfusions for Low Amniotic Fluid
Rochester, Minnesota
This trial tests a method of injecting fluid into the womb of pregnant women whose fetuses have a severe kidney condition that prevents normal lung development. The goal is to help the fetus's lungs grow so they can survive after birth. The trial focuses on the safety and effectiveness of this treatment for fetuses with urinary tract issues.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cervical Length, Congenital Anomalies, Others
70 Participants Needed
LYL797 for Breast and Lung Cancer
Rochester, Minnesota
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Organ Transplant, Brain Metastasis, HIV, Others
Must Not Be Taking:Corticosteroids, Immunosuppressives
100 Participants Needed
RP-6306 + Gemcitabine for Advanced Cancer
Rochester, Minnesota
The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Not Listed
104 Participants Needed
Mosunetuzumab for Chronic Lymphocytic Leukemia
Rochester, Minnesota
This trial is testing a new drug called mosunetuzumab, both alone and with another drug called venetoclax, in patients with a type of blood cancer that has come back or not responded to treatment. Mosunetuzumab helps the immune system attack cancer cells, while venetoclax helps kill the cancer cells. Venetoclax has been used with other drugs to help treat different types of blood cancers.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Infections, HIV, Others
Must Be Taking:BTKi
137 Participants Needed
LY3410738 for Solid Tumors
Rochester, Minnesota
This trial is testing a new oral drug called LY3410738 in patients with advanced solid tumors that have specific genetic mutations. The drug works by blocking abnormal enzymes to potentially stop or slow cancer growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Active CNS Metastases, Uncontrolled Cardiac Disease, Others
Must Not Be Taking:Strong CYP3A4 Inhibitors, P-gp Inhibitors
200 Participants Needed
Cognitive Training for Breast Cancer Survivors
Mankato, Minnesota
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Other Cancer, CNS Radiation, Stroke, Substance Abuse, Others
386 Participants Needed
Gluten Challenge for Celiac Disease
Rochester, Minnesota
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Severe Celiac, GI Disease, Others
Must Not Be Taking:Antibiotics, PPIs, NSAIDs, Others
220 Participants Needed
Health Coaching for Lung Transplant Candidates
Rochester, Minnesota
To examine the effectiveness of an individual health coaching intervention for lung transplant candidates. This intervention will include up to 12 health coaching sessions via phone call over a 12-16 week period. This will be compared to a usual care group the receives pre-transplant care and education alone.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Under 18, Non-English, Nonverbal, Others
230 Participants Needed
CardioMech MVRS for Mitral Valve Regurgitation
Rochester, Minnesota
This trial is testing a new device called the CardioMech Mitral Valve Repair System (MVRS) to help patients with a leaky heart valve who are at high risk for surgery. The device aims to fix the valve and improve heart function without needing open-heart surgery. The HARPOON Beating Heart Mitral Valve Repair System (MVRS) has shown it can safely and effectively repair the heart valve while the heart is still beating.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Rheumatic Heart Disease, Prior Endocarditis, Others
25 Participants Needed
Autonomic Function Testing for Spinal Cord Injury
Rochester, Minnesota
This study looks to characterize gradients of dysfunction in the autonomic nervous system after spinal cord injury. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with spinal cord injury typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with spinal cord injury and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction after spinal cord injury will exhibit abnormalities in these precise metrics. The investigators will further have research participants wear a smart watch that tracks skin electrical conductance, heart rate, and skin temperature, which can all provide clues as to the degree of autonomic dysfunction someone may suffer at home. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from spinal cord injury. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after spinal cord injury and give physicians better tools to manage these secondary autonomic complications.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Hypertension, Diabetes, Others
Must Not Be Taking:Blood Thinners
69 Participants Needed
HARPOON™ System for Mitral Valve Regurgitation
Rochester, Minnesota
The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative mitral regurgitation (DMR).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21+
Key Eligibility Criteria
Disqualifiers:Severe Pulmonary Hypertension, Severe Aortic Stenosis, Severe Tricuspid Regurgitation, Renal Insufficiency, Others
25 Participants Needed
Why Other Patients Applied
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
MID-C System for Adolescent Idiopathic Scoliosis
Rochester, Minnesota
The ApiFix MID-C System is a unidirectional expandable rod, designed to be connected unilaterally to the spine via 2 anchor points on the concave side of a scoliotic deformity above and below the apex of the major curvature to treat adolescent idiopathic scoliosis. The MID-C System is designed to act as an internal brace. Patients implanted with the device in the US within 2 years of FDA's approval of H17001 should be enrolled in the study. A minimum number of 200 patients will be enrolled in this study.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:10+
Key Eligibility Criteria
Disqualifiers:Non-idiopathic Scoliosis, Malignancy, Neurological Deficit, Others
201 Participants Needed
Laminectomy vs Fusion for Lumbar Spinal Stenosis
Rochester, Minnesota
The purpose of the project is to perform an RCT comparing patient satisfaction and outcome with or without the use of an expert panel. The purpose is also to create a registry to compare the effectiveness of decompression alone versus decompression with fusion for patients with degenerative grade I spondylolisthesis and symptomatic lumbar spinal stenosis. Primary analysis will focus on the patients' improvement from baseline patient-reported outcome questionnaires.
In addition, the SLIP II registry aims to (i) develop an algorithm which could identify cases in which surgical experts are likely to recommend one treatment (i.e. \>80% of experts recommend one form of treatment) and (ii) develop a radiology-based machine learning algorithm that would prospectively classify patients as either 'stable' or 'unstable.'
In addition to patient reported outcomes, step counts will be collected in order to determine the correlation of step count with patient-reported outcomes (ODI and EQ-5D) and the need for re-operation.
This registry portion of the study aims to prospectively collect comparative data for these patients treated with either decompression alone or decompression with fusion.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Serious Illness, Spondylolysis, Multilevel Spondylolisthesis, Others
662 Participants Needed
TIMMY3 Thermometer for Fever
Mankato, Minnesota
The purpose of this document is to validate the clinical accuracy of the TIMMY3 thermometry module, integrated into host device CVSM, according to ISO 80601-2-56:2017 + A1 2018.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:1 - 99
Key Eligibility Criteria
Disqualifiers:Anatomical Abnormalities, Neutropenic, Others
Must Not Be Taking:Antipyretics, Barbiturates, Antipsychotics
420 Participants Needed
Smoking Cessation Interventions for Quitting Smoking
Rochester, Minnesota
This project will evaluate a proactive outreach intervention for tobacco cessation among primary care BIPOC populations who smoke in two health systems across the region. Compared with Whites, BIPOC populations in the US experience disproportionate health consequences from commercial cigarette use. Few evidence-based cessation treatments (EBCTs) have been specifically developed, evaluated, or implemented for BIPOC populations. Moreover, uptake of EBCT (e.g. medication, counseling) is lower among BIPOC populations. Reasons for the failure to engage BIPOC patients in EBCTs are complex and multi-level (e.g., patient, provider, healthcare system). To address these gaps, the investigators will assess the added effectiveness of an approach to augment the standard of care with longitudinal proactive outreach to connect BIPOC adults with EBCT. The proposed multi-level intervention leverages the electronic health record to identify patients who smoke, who can then be proactively engaged via culturally tailored outreach to connect them to EBCT. The proactive approach may circumvent experiences of bias within the healthcare system and thus enhance engagement.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Cognitive Impairment, Legal Guardianship, Others
2000 Participants Needed
Proton Therapy vs. Photon Radiation for Prostate Cancer
Mankato, Minnesota
This study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes \[quality of life (QOL), toxicity, and disease control\] between parallel cohorts of men with prostate cancer treated simultaneously at proton therapy facilities and at geographically similar conventional (photon-based) radiation facilities using intensity-modulated radiation therapy (IMRT) techniques.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:30 - 85
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Very High-risk Cancer, Prior Prostate Procedures, Invasive Pelvic Malignancy, Others
3000 Participants Needed
tRNS for ADHD
Rochester, Minnesota
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 12
Key Eligibility Criteria
Disqualifiers:Severe ODD, Bipolar, Substance Abuse, Others
Must Not Be Taking:ADHD Medications
146 Participants Needed
MPK vs NMPK Prosthetics for Above-Knee Amputation
Rochester, Massachusetts
This trial tests advanced artificial knees with built-in computers in above-knee or knee-level amputees who have limited walking ability. The goal is to see if these knees can reduce fear of falling, improve quality of life, and increase participation in activities. These advanced knees are well-established devices that significantly increase patient safety, walking ability, and performance in daily activities.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:65+
Key Eligibility Criteria
Disqualifiers:Upper Limb Involvement, Active Malignancy, Others
107 Participants Needed
Dexpramipexole for Eosinophilic Asthma
Mankato, Minnesota
This trial is testing an oral medication called dexpramipexole to help people with a type of asthma that isn't well controlled by their current treatments. The medication works by reducing specific white blood cells that cause inflammation, which may improve breathing and asthma control.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:12 - 99
Key Eligibility Criteria
Disqualifiers:Not Listed
550 Participants Needed
Letrozole for Hormone Receptor-Positive Breast Cancer
Mankato, Minnesota
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Sex:Female
Key Eligibility Criteria
Disqualifiers:Not Listed
3966 Participants Needed
Poly-ICLC for Low-Grade Glioma
Minneapolis, Minnesota
This trial is testing a medication called Poly-ICLC that boosts the immune system in children with NF1 who have brain tumors that don't respond to usual treatments. The goal is to see if this medication can help shrink or control the tumors by enhancing the body's natural defenses.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:< 22
Key Eligibility Criteria
Disqualifiers:Radiation Treatment, Malignant Glioma, Others
Must Not Be Taking:Steroids, Immunosuppressants
20 Participants Needed
Know someone looking for new options?
Spread the word